Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The crux of the UGDP. Spurious results and biologically inappropriate data analysis.

Literature DB >> 6989693

The crux of the UGDP. Spurious results and biologically inappropriate data analysis.

C Kilo, J P Miller, J R Williamson.

Abstract

Mesh：

Substances：

Year: 1980 PMID： 6989693 DOI： 10.1007/BF00251913

Source DB: PubMed Journal: Diabetologia ISSN： 0012-186X Impact factor: 10.122

× No keyword cloud information.

19 in total

1. Clinical biostatistics. XXXV. The persistent clinical failures and fallacies of the UGDP study.

Authors: A R Feinstein
Journal: Clin Pharmacol Ther Date: 1976-01 Impact factor: 6.875

2. Decisive factors in the tolbutamide controversy.

Authors: J B O'Sullivan; R B D'Agostino
Journal: JAMA Date: 1975-05-26 Impact factor: 56.272

3. "Settling the UGDP controversy"?

Authors: R F Bradley; H Dolger; P H Forsham; H Seltzer
Journal: JAMA Date: 1975-05-26 Impact factor: 56.272

4. Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents.

Authors:
Journal: JAMA Date: 1975-02-10 Impact factor: 56.272

5. Letter: The UGDP scandal and cover-up.

Authors: J M Moss
Journal: JAMA Date: 1975-05-26 Impact factor: 56.272

Review 6. How good is the statistical evidence against oral hypoglycemic agents?

Authors: A R Feinstein
Journal: Adv Intern Med Date: 1979

7. Diabetes drugs: clinical trial.

Authors: T E Prout; G L Knatterud; C G Meinert
Journal: Science Date: 1979-04-27 Impact factor: 47.728

8. The University Group Diabetes Program. A statistician looks at the mortality results.

Authors: S Schor
Journal: JAMA Date: 1971-09-20 Impact factor: 56.272

9. Refuting the UGDP conclusion that insulin treatment does not prevent vascular complications in diabetes.

Authors: C Kilo; J R Williamson; S C Choi; J P Miller
Journal: Adv Exp Med Biol Date: 1979 Impact factor: 2.622

10. Correlation of serum triglyceride levels and hemoglobin AIc concentrations in diabetes mellitus.

Authors: C M Peterson; R J Koenig; R L Jones; C D Saudek; A Cerami
Journal: Diabetes Date: 1977-05 Impact factor: 9.461

16 in total

1. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.

Authors: Giovanni Corrao; Silvana Antonietta Romio; Antonella Zambon; Luca Merlino; Emanuele Bosi; Marina Scavini
Journal: Eur J Clin Pharmacol Date: 2010-11-19 Impact factor: 2.953

6. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year.

Authors:
Journal: Diabetologia Date: 1983-06 Impact factor: 10.122

The crux of the UGDP. Spurious results and biologically inappropriate data analysis.

1. Clinical biostatistics. XXXV. The persistent clinical failures and fallacies of the UGDP study.

2. Decisive factors in the tolbutamide controversy.

3. "Settling the UGDP controversy"?

4. Report of the Committee for the Assessment of Biometric Aspects of Controlled Trials of Hypoglycemic Agents.

5. Letter: The UGDP scandal and cover-up.

Review 6. How good is the statistical evidence against oral hypoglycemic agents?

7. Diabetes drugs: clinical trial.

8. The University Group Diabetes Program. A statistician looks at the mortality results.

9. Refuting the UGDP conclusion that insulin treatment does not prevent vascular complications in diabetes.

10. Correlation of serum triglyceride levels and hemoglobin AIc concentrations in diabetes mellitus.

1. Multiple outcomes associated with the use of metformin and sulphonylureas in type 2 diabetes: a population-based cohort study in Italy.

Review 2. Treatment of diabetes: the effect on serum lipids and lipoproteins.

3. Treatment of type II diabetes.

Review 4. The use of sulphonylureas in the elderly.

Review 5. Oral antihyperglycemic therapy for type 2 diabetes mellitus.

6. UK prospective study of therapies of maturity-onset diabetes. I. Effect of diet, sulphonylurea, insulin or biguanide therapy on fasting plasma glucose and body weight over one year.

Review 7. Comparative tolerability of sulphonylureas in diabetes mellitus.

Review 8. Oral antidiabetic drug use in the elderly.

Review 9. Prevention of complications in non-insulin-dependent diabetes mellitus (NIDDM).

Review 10. Comparative tolerability profiles of oral antidiabetic agents.